TrialNature communications2026

Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM).

Bo Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.